Compare BAK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAK | PHAR |
|---|---|---|
| Founded | 1972 | 1988 |
| Country | Brazil | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2002 | 2020 |
| Metric | BAK | PHAR |
|---|---|---|
| Price | $3.86 | $16.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.40 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 2.4M | 6.5K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.02 | $10.04 |
| Revenue Next Year | $7.04 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $8.60 |
| 52 Week High | $5.30 | $21.34 |
| Indicator | BAK | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 46.37 |
| Support Level | $3.34 | $15.96 |
| Resistance Level | $3.97 | $17.28 |
| Average True Range (ATR) | 0.20 | 0.37 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 76.22 | 5.11 |
Braskem SA is engaged in the manufacture, sale, import and export of chemicals, petrochemicals and fuels, as well as the production, supply and sale of utilities such as steam, water, compressed air and industrial gases. It also provides industrial services and is engaged in the production, supply and sale of electric energy and gas for its own use and use by other companies. Its segments include Brazil, USA and Europe; and Mexico. The Brazil segments delivered the majority of the revenue from the production and sale of chemicals; the supply of electricity and other inputs produced in these complexes to second-generation producers located in the petrochemical complexes; and the production and sale of PE, including the production of green PE made from renewable resources, and of PP.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.